{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:00:35Z","timestamp":1793923235140,"version":"4.8.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.annonc.2021.11.005","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T14:37:58Z","timestamp":1638283078000},"page":"129-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":237,"title":["Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606"],"prefix":"10.1016","volume":"33","author":[{"given":"S.","family":"Popat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Baas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Opitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 1","key":"10.1016\/j.annonc.2021.11.005_bib1","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.21037\/tlcr.2019.11.11","article-title":"Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted\/banned asbestos use","volume":"9","author":"Alpert","year":"2020","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib2","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1001\/jamaoncol.2019.0446","article-title":"High time for complete ban on asbestos use in developing countries","volume":"5","author":"Chen","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib3","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1002\/ijc.32931","article-title":"Survival of malignant mesothelioma and other rare thoracic cancers in Germany and the United States: a population-based study","volume":"147","author":"Sirri","year":"2020","journal-title":"Int J Cancer"},{"key":"10.1016\/j.annonc.2021.11.005_bib5","series-title":"National Mesothelioma Audit Report 2020 (Audit Period 2016-18)","year":"2020"},{"issue":"9366","key":"10.1016\/j.annonc.2021.11.005_bib6","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(03)13079-6","article-title":"Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial","volume":"361","author":"Maskell","year":"2003","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.annonc.2021.11.005_bib7","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/cncr.23034","article-title":"Accuracy of pleural biopsy using thoracoscopy for the diagnosis of histologic subtype in patients with malignant pleural mesothelioma","volume":"110","author":"Greillier","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib8","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/BF03256303","article-title":"Biomarkers for malignant pleural mesothelioma: current status","volume":"12","author":"Greillier","year":"2008","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.annonc.2021.11.005_bib9","series-title":"Thoracic Tumours","year":"2020"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41379-019-0352-3","article-title":"Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel","volume":"33","author":"Marchevsky","year":"2020","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.annonc.2021.11.005_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.11.005_bib12","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annonc.2021.11.005_bib13","series-title":"IASLC Atlas of Diagnostic Immunohistochemistry","first-page":"157","article-title":"Mesothelioma and immunohistochemsitry","author":"Papotti","year":"2020"},{"issue":"1","key":"10.1016\/j.annonc.2021.11.005_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5858\/arpa.2017-0124-RA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group","volume":"142","author":"Husain","year":"2018","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"10.1016\/j.annonc.2021.11.005_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/PAS.0000000000001416","article-title":"Utility of nuclear grading system in epithelioid malignant pleural mesothelioma in biopsy-heavy setting: an external validation study of 563 cases","volume":"44","author":"Zhang","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","volume":"33","author":"Churg","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.annonc.2021.11.005_bib18","series-title":"TNM Classification of Malignant Tumours","first-page":"113","article-title":"Pleural mesothelioma","year":"2017"},{"issue":"12","key":"10.1016\/j.annonc.2021.11.005_bib19","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","article-title":"The IASLC mesothelioma staging project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Rice","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.11.005_bib20","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC mesothelioma staging project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jtho.2015.10.003","article-title":"Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma","volume":"11","author":"Bill\u00e9","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1510\/icvts.2010.255893","article-title":"What is the best way to diagnose and stage malignant pleural mesothelioma?","volume":"12","author":"Zahid","year":"2011","journal-title":"Interact Cardiovasc Thorac Surg"},{"issue":"12","key":"10.1016\/j.annonc.2021.11.005_bib23","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC mesothelioma staging project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.11.005_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/SLA.0000000000000903","article-title":"Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients","volume":"260","author":"Sugarbaker","year":"2014","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib25","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/ejcts\/ezv422","article-title":"Specimen weight and volume: important predictors of survival in malignant pleural mesothelioma","volume":"49","author":"Kircheva","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1","key":"10.1016\/j.annonc.2021.11.005_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ejcts\/ezaa158","article-title":"ERS\/ESTS\/EACTS\/ESTRO guidelines for the management of malignant pleural mesothelioma","volume":"58","author":"Opitz","year":"2020","journal-title":"Eur J Cardiothorac Surg"},{"issue":"9948","key":"10.1016\/j.annonc.2021.11.005_bib27","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0140-6736(14)60418-9","article-title":"Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial","volume":"384","author":"Rintoul","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib28","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.athoracsur.2014.02.027","article-title":"A\u00a0propensity-matched comparison of pleurodesis or tunneled pleural catheter for heart failure patients with recurrent pleural effusion","volume":"97","author":"Freeman","year":"2014","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"10.1016\/j.annonc.2021.11.005_bib29","doi-asserted-by":"crossref","first-page":"e000368","DOI":"10.1136\/bmjresp-2018-000368","volume":"6","author":"Matthews","year":"2019","journal-title":"BMJ Open Resp Res"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A\u00a0systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib31","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.athoracsur.2014.09.056","article-title":"Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma","volume":"99","author":"Taioli","year":"2015","journal-title":"Ann Thorac Surg"},{"issue":"8","key":"10.1016\/j.annonc.2021.11.005_bib32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","article-title":"National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study","volume":"105","author":"Saddoughi","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.annonc.2021.11.005_bib34","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.lungcan.2018.10.009","article-title":"Real-life treatment practice for malignant pleural mesothelioma in Belgium","volume":"125","author":"Rosskamp","year":"2018","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.annonc.2021.11.005_bib35","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1016\/j.annonc.2021.11.005_bib36","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.11.005_bib37","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0169-5002(03)91714-4","article-title":"O-56 Symptom and quality of life advantages for pemetrexed\u00a0+ cisplatin versus cisplatin in treatment of malignant pleural mesothelioma","volume":"41","author":"Boyer","year":"2003","journal-title":"Lung Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2021.11.005_bib38","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/JTO.0b013e31817c73ec","article-title":"Single-agent pemetrexed for chemona\u00efve and pretreated patients with malignant pleural mesothelioma: results of an international expanded access program","volume":"3","author":"Taylor","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10272","key":"10.1016\/j.annonc.2021.11.005_bib39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"issue":"10026","key":"10.1016\/j.annonc.2021.11.005_bib40","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.annonc.2021.11.005_bib41","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1158\/1078-0432.CCR-18-2860","article-title":"Health-related quality of life impact from adding bevacizumab to cisplatin-pemetrexed in malignant pleural mesothelioma in the MAPS IFCT-GFPC-0701 phase III trial","volume":"25","author":"Eberst","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.annonc.2021.11.005_bib42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.annonc.2021.11.005_bib43","doi-asserted-by":"crossref","first-page":"S1341","DOI":"10.1016\/j.annonc.2021.08.2146","article-title":"LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743","volume":"32","author":"Peters","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2021.11.005_bib44","doi-asserted-by":"crossref","first-page":"S1441","DOI":"10.1016\/j.annonc.2020.10.603","article-title":"LBA1 First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): patient-reported outcomes (PROs) from CheckMate 743","volume":"31","author":"Scherpereel","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.11.005_bib45","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib46","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.cllc.2020.06.025","article-title":"Randomized study of maintenance pemetrexed versus observation for treatment of malignant pleural mesothelioma: CALGB 30901","volume":"21","author":"Dudek","year":"2020","journal-title":"Clin Lung Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib47","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2213-2600(20)30362-3","article-title":"Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial","volume":"9","author":"de Gooijer","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.annonc.2021.11.005_bib48","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1200\/JCO.2018.79.0543","article-title":"Maintenance defactinib versus placebo after first-line chemotherapy in patients with Merlin-Stratified pleural mesothelioma: COMMAND\u2014a double-blind, randomized, phase II study","volume":"37","author":"Fennell","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.11.005_bib49","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/JCO.2021.39.15_suppl.8507","article-title":"A\u00a0randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma","volume":"39","author":"Fennell","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.11.005_bib50","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/j.annonc.2020.09.009","article-title":"A\u00a0multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"31","author":"Popat","year":"2020","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2021.11.005_bib51","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2021.11.005_bib52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"issue":"suppl 15","key":"10.1016\/j.annonc.2021.11.005_bib53","doi-asserted-by":"crossref","first-page":"8565","DOI":"10.1200\/JCO.2018.36.15_suppl.8565","article-title":"Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM)","volume":"36","author":"Desai","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2021.11.005_bib54","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.11.005_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"issue":"18","key":"10.1016\/j.annonc.2021.11.005_bib56","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2021.11.005_bib58","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","article-title":"Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial","volume":"22","author":"Fennell","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2021.11.005_bib59","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.rmed.2018.06.026","article-title":"A\u00a0systematic review and meta-analysis of second-line therapies for treatment of mesothelioma","volume":"141","author":"Petrelli","year":"2018","journal-title":"Respir Med"},{"issue":"10","key":"10.1016\/j.annonc.2021.11.005_bib60","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S1470-2045(21)00404-6","article-title":"Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"22","author":"Pinto","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.11.005_bib61","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1038\/s41598-020-62813-2","article-title":"Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition","volume":"10","author":"Ghanim","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib62","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S2213-2600(18)30151-6","article-title":"Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study","volume":"6","author":"Calabr\u00f2","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.annonc.2021.11.005_bib63","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.annonc.2021.11.005_bib64","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.annonc.2021.11.005_bib65","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"10.1016\/j.annonc.2021.11.005_bib66","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1158\/1078-0432.CCR-20-4037","article-title":"Alterations in BAP1 are associated with cisplatin resistance through inhibition of apoptosis in malignant pleural mesothelioma","volume":"27","author":"Oehl","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.annonc.2021.11.005_bib67","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib68","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(20)30390-8","article-title":"Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial","volume":"9","author":"Fennell","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib69","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.lungcan.2013.11.004","article-title":"Radiotherapy for the treatment of pain in malignant pleural mesothelioma: a systematic review","volume":"83","author":"Macleod","year":"2014","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib70","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1097\/JTO.0000000000000499","article-title":"Is radiotherapy useful for treating pain in mesothelioma? A phase II trial","volume":"10","author":"MacLeod","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2021.11.005_bib71","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(16)30095-X","article-title":"Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial","volume":"17","author":"Clive","year":"2016","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2021.11.005_bib72","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.18.01678","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, phase III randomized trial","volume":"37","author":"Bayman","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2021.11.005_bib73","doi-asserted-by":"crossref","first-page":"103278","DOI":"10.1016\/j.critrevonc.2021.103278","article-title":"Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: a systematic review and meta-analysis of randomized trials","volume":"160","author":"Lee","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"10.1016\/j.annonc.2021.11.005_bib74","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.radonc.2009.03.011","article-title":"Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"92","author":"Kristensen","year":"2009","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2021.11.005_bib75","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/JTO.0b013e318272601f","article-title":"Tomotherapy after pleurectomy\/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung","volume":"7","author":"Minatel","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib76","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ijrobp.2007.03.011","article-title":"Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma","volume":"69","author":"Rice","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16","key":"10.1016\/j.annonc.2021.11.005_bib77","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/S1470-2045(15)00208-9","article-title":"Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17\/04): a randomised, international, multicentre phase 2 trial","volume":"16","author":"Stahel","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2021.11.005_bib78","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ijrobp.2015.06.029","article-title":"Radical radiation therapy after lung-sparing surgery for malignant pleural mesothelioma: survival, pattern of failure, and prognostic factors","volume":"93","author":"Minatel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"23","key":"10.1016\/j.annonc.2021.11.005_bib79","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2021.11.005_bib80","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijrobp.2017.04.025","article-title":"Heart dosimetry is correlated with risk of radiation pneumonitis after lung-sparing hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma","volume":"99","author":"Yorke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib81","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jtcvs.2015.09.129","article-title":"Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"151","author":"de Perrot","year":"2016","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.annonc.2021.11.005_bib82","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3389\/fonc.2019.00961","article-title":"Stereotactic body radiation therapy (SBRT) as salvage therapy for oligorecurrent pleural mesothelioma after multi-modality therapy","volume":"9","author":"Schr\u00f6der","year":"2019","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2021.11.005_bib83","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1120\/jacmp.v16i6.5678","article-title":"Beam-specific planning target volumes incorporating 4D CT for pencil beam scanning proton therapy of thoracic tumors","volume":"16","author":"Lin","year":"2015","journal-title":"J\u00a0Appl Clin Med Phys"},{"issue":"1","key":"10.1016\/j.annonc.2021.11.005_bib84","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/php.13065","article-title":"A\u00a0novel prospective study assessing the combination of photodynamic therapy and proton radiation therapy: safety and outcomes when treating malignant pleural mesothelioma","volume":"95","author":"Rice","year":"2019","journal-title":"Photochem Photobiol"},{"issue":"9","key":"10.1016\/j.annonc.2021.11.005_bib85","first-page":"S224","article-title":"ORAL26.06 prospective assessment of proton therapy for malignant pleural mesothelioma","volume":"10","author":"Li","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2021.11.005_bib87","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1136\/thoraxjnl-2018-212380","article-title":"Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial","volume":"74","author":"Brims","year":"2019","journal-title":"Thorax"},{"issue":"9","key":"10.1016\/j.annonc.2021.11.005_bib88","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S2213-2600(18)30288-1","article-title":"Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial","volume":"6","author":"Muruganandan","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.annonc.2021.11.005_bib89","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1038\/s41430-019-0418-9","article-title":"Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life","volume":"73","author":"Jeffery","year":"2019","journal-title":"Eur J Clin Nutr"},{"issue":"3","key":"10.1016\/j.annonc.2021.11.005_bib90","doi-asserted-by":"crossref","first-page":"100092","DOI":"10.1016\/j.esmoop.2021.100092","article-title":"Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines","volume":"6","author":"Arends","year":"2021","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.annonc.2021.11.005_bib91","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised modified response evaluation criteria in solid tumors for assessment of response in malignant pleural mesothelioma (Version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2021.11.005_bib92","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2021.11.005_bib93","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421048201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753421048201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T06:06:31Z","timestamp":1760335591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753421048201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0923753421048201"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2021.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Society for Medical Oncology. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}